Skip to content

Multiparameter ultrasound for the detection of prostate cancer, a multicenter study

Multiparameter ultrasound for the detection of prostate cancer, a multicenter study

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092917
Enrollment
Unknown
Registered
2024-11-26
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Cancer

Interventions

Gold Standard:The results of MPUS-TB and TRUS-SB are obtained from the same patient. The gold standard is the pathological diagnosis as csPCa and cisPCa.
Index test:multi-parameter ultrasound targeted biopsy transrectal ultrasound systematic biopsy

Sponsors

Sichuan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients over the age of 18 years with a first occurrence of elevated serum PSA concentration or abnormal digital rectal examination for suspected prostate cancer, or who have had a previous prostate biopsy and need to stratified cancer risk before entering the active surveillance phase 2) Prostate mpUS examination was performed before prostate biopsy, and the time interval between mpUS and biopsy was less than 3 months.

Exclusion criteria

Exclusion criteria: 1) Serum PSA concentration over 20 ng/mL. 2) There are contraindications: irreversible coagulation dysfunction; Have been treated for prostate cancer (including radiotherapy, high intensity focused ultrasound, cryotherapy, hyperthermia, etc.); Or urethral prostate surgery within 6 months prior to enrollment 3) There is contraindication of transrectal mpUS (including hypersensitivity to contrast media). 4) Patients with imaging signs of lymph node or metastatic prostate cancer. 5) Any history of hormonal regulation or androgen deprivation in the 6 months prior to screening

Design outcomes

Primary

MeasureTime frame
To compare the proportion of patients with csPCa (using definition A, defined as Gleason = 7) detected by MPUS-TB and TRUS-SB.;

Secondary

MeasureTime frame
Compare the proportion of patients with csPCa detected by MPUS-TB and TRUS-SB (using definition B, i.e., any Gleason grade =7 or Gleason 6 with at least one sample having MCCL=6mm);Compare the proportion of patients with cisPCa detected by MPUS-TB and TRUS-SB (defined as Gleason grade =6, positive samples =2, and positive samples with MCCL 50 mL - Among patients undergoing TB, mpUS, mpMRI, or US/MRI fusion guidance were used, respectively;The proportion of patients with a negative MPUS result converted to a positive MPUS result and/or Gleason grade =7 within two years;To compare the incidence of adverse events after biopsy between MPUS-TB and TRUS-SB;health-related quality of life scores;

Countries

China

Contacts

Public ContactJinshun Xu

Sichuan Cancer Hospital

xunjinshun@uestc.edu.cn+86 187 0849 1127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026